On March 4, 2025 Lirum Therapeutics, Inc. ("Lirum"), an innovative clinical-stage biopharmaceutical company focused on the treatment of debilitating diseases, reported the presentation of additional positive data on LX-101 at the 2025 ESMO (Free ESMO Whitepaper) Targeted Anticancer Therapies Congress (TAT) in Paris, France (Press release, Lirum Therapeutics, MAR 4, 2025, View Source [SID1234651608]). LX-101, a novel clinical-stage payload-bearing targeted therapy directed to the insulin-like growth factor 1 receptor (IGF-1R), was selected for two presentations at this year’s TAT conference.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The first presentation, co-authored with investigators from the MD Anderson Cancer Center, showcases LX-101’s strong in vivo activity in Ewing sarcoma as well as its potency in in vitro models of both Ewing sarcoma and desmoplastic small round cell tumor (DSRCT). These cancers have strong ties to IGF-1R, including DNA-level gene fusions that affect this signaling pathway. The second presentation highlights LX-101’s broad potency against a host of IGF-1R-expressing cell lines from a number of additional adult cancers including lung, esophageal and stomach cancers, which represent large market opportunities. These presentations underscore LX-101’s potent activity and promise in both pediatric and adult cancers with well-established ties to the IGF-1R pathway.
The presentations are entitled:
LX-101, a Novel, Clinical Stage, Payload-Bearing Targeted Therapy Directed to the Insulin-Like Growth Factor Receptor (IGF-1R), Demonstrates Potent Anti-Tumor Activity in Ewing Sarcoma Animal Models and Desmoplastic Small Round Cell Tumors, and
LX-101, a Novel, Clinical Stage, Payload-Bearing Targeted Therapy Directed to the Insulin-Like Growth Factor Receptor (IGF-1R), Demonstrates Potent Preclinical Anti-Tumor Activity Against Multiple Cancer Types with Elevated IGF-1R Expression.
Both presentations are available on the Lirum website (www.lirumtx.com) under the Investors and Media tab.
Given these promising results, new clinical trials with LX-101 are planned in pediatric indications that carry strong ties to the IGF-1/IGF-1R pathway, including Ewing Sarcoma, DSRCT, rhabdomyosarcoma, and GIST. In addition, Lirum is planning trials in adult patients with cancer types that are naturally enriched for IGF-1R, including certain head and neck indications and others. In parallel, Lirum is also focused on developing LX-101 in thyroid eye disease (TED), where IGF-1R has been clinically and commercially validated.